Download Free Risking Antimicrobial Resistance Book in PDF and EPUB Free Download. You can read online Risking Antimicrobial Resistance and write the review.

Antimicrobial resistance (AMR) is predicted to be one of the greatest threats to public health in the twenty-first century. In this context, understanding the reasons why perceptions of antibiotic risk differ between different groups is crucial when it comes to tackling antibiotic misuse. This innovative volume gathers together chapters written by sociologists, psychologists and linguists with the common aim of examining the social factors that affect use of antibiotics among humans and animals. A unique focus on Denmark – one of the world’s most progressive countries when it comes to antibiotic regulation – as well as Europe more broadly, makes this book a valuable resource for regulatory deliberations on future antibiotic policy to effectively combat AMR.
This Open Access volume provides in-depth analysis of the wide range of ethical issues associated with drug-resistant infectious diseases. Antimicrobial resistance (AMR) is widely recognized to be one of the greatest threats to global public health in coming decades; and it has thus become a major topic of discussion among leading bioethicists and scholars from related disciplines including economics, epidemiology, law, and political theory. Topics covered in this volume include responsible use of antimicrobials; control of multi-resistant hospital-acquired infections; privacy and data collection; antibiotic use in childhood and at the end of life; agricultural and veterinary sources of resistance; resistant HIV, tuberculosis, and malaria; mandatory treatment; and trade-offs between current and future generations. As the first book focused on ethical issues associated with drug resistance, it makes a timely contribution to debates regarding practice and policy that are of crucial importance to global public health in the 21st century.
"In May 2015, the Sixty-eighth World Health Assembly adopted the Global action plan on antimicrobial resistance, which reflects the global consensus that AMR poses a profound threat to human health. One of the five strategic objectives of the Global action plan is to strengthen the evidence base through enhanced global surveillance and research. The Global Antimicrobial Resistance Surveillance System (GLASS) has been developed to facilitate and encourage a standardized approach to AMR surveillance globally and in turn support the implementation of the Global action plan on antimicrobial resistance. This manual addresses the early phase of implementation of GLASS, focussing on surveillance of resistance in common human bacterial pathogens. The intended readership of this publication is public health professionals and health authorities responsible for national AMR surveillance. It outlines the GLASS standards and describes the road map for implementation of the system between 2015 and 2019. Further development of GLASS will be based on the lessons learnt during this period"--Publisher's description.
Avoiding infection has always been expensive. Some human populations escaped tropical infections by migrating into cold climates but then had to procure fuel, warm clothing, durable housing, and crops from a short growing season. Waterborne infections were averted by owning your own well or supporting a community reservoir. Everyone got vaccines in rich countries, while people in others got them later if at all. Antimicrobial agents seemed at first to be an exception. They did not need to be delivered through a cold chain and to everyone, as vaccines did. They had to be given only to infected patients and often then as relatively cheap injectables or pills off a shelf for only a few days to get astonishing cures. Antimicrobials not only were better than most other innovations but also reached more of the world’s people sooner. The problem appeared later. After each new antimicrobial became widely used, genes expressing resistance to it began to emerge and spread through bacterial populations. Patients infected with bacteria expressing such resistance genes then failed treatment and remained infected or died. Growing resistance to antimicrobial agents began to take away more and more of the cures that the agents had brought.
Discusses the way leaders deal with risk in making foreign policy decisions
Veterinary pharmaceuticals provide animals with the requisite, complete animal health care. The availability of safe and good quality medicines in the right amounts is needed in achieving optimum animal health care. The economic benefits of animal food products cannot be under-estimated. Veterinary pharmaceuticals are needed to meet the ever-growing demand of animal protein for the human population. However, their routine and unguarded use play significant roles in many public health issues, such as antimicrobial resistance. The practices, knowledge, and awareness needed on the use and application of veterinary pharmaceuticals amongst farmers, animal health professionals, microbiologists, and policy makers remain key in ensuring a safe and healthy food chain for all. In the field of veterinary medicine, canine practice is a challenge to veterinarians. In recent years, newer diagnostic methods and therapeutic protocols have been published on a regular basis. Along with the existing knowledge of important canine diseases like ascites, duodenal disorders, pericardial effusions, and canine mastitis, this book is supplemented with all the latest information. Discussion of duodenal disorders in dogs, including IBD and SIBO, is an important topic in day-to-day practice. Ascites and mastitis in dogs are also important topics and are discussed in this book. Each topic carries practical points for the diagnosis and management of important diseases of dogs. Hence, this book will be very useful for canine practitioners.
During the post-World War II "wonder drug" revolution, antibiotics were viewed as a panacea for mastering infectious disease. This book narrates the far-reaching history of antibiotics, focusing particularly on reform efforts that attempted to fundamentally change how antibiotics are developed and prescribed
"I would definitely recommend this book to all staff with an interest and involvement in intravenous drug therapy." —The Pharmaceutical Journal "There is no doubt that nurses will find this small book useful. It should be available for consultation in any clinical area where drugs are administered to patients by the injectable routes." —Journal of Clinical Nursing The safe administration of injectable medicines is key to patient safety. The NPSA recognises the use of injectable medicines is a high risk activity and recommends written information about injectables to be available at the point of preparation. The UCL Hospitals Injectable Medicines Administration Guide is a practical, accessible guide covering many important aspects of administering medicines by injection. It provides clear, concise information on the preparation and administration of over 245 injectable medicines for adults, paediatrics and neonates. It is an essential resource for nurses and other healthcare professionals: it provides the key information and advice needed for the safe and effective administration of injectable medicines. The Guide’s introductory section provides a concise yet comprehensive overview of injectable therapy, including the risks and benefits of IV administration, infusion devices, and pharmaceutical aspects of injectable therapy. For each drug the alphabetically tabulated monographs provide: A practical method of preparation and administration via the IV, IM and SC routes, with risk reduction in mind at every step Expert advice from the team of specialist pharmacists at UCLH to ensure safe and pragmatic use of each medicine Monitoring advice for the management of reactions that may occur during administration Y-site and syringe driver compatibility data Minimum infusion volume data for fluid restricted patients Extravasation warnings, pH, sodium content, displacement values, stability and flush data New to this edition: 40 new monographs including recently marketed, unlicensed, rarely used and specialist medicines Detailed advice for the administration of high risk medicines such as heparin, with access to UCLH’s medicine related guidelines at www.wiley.com/go/UCLH A colour-coded NPSA risk assessment for every mode of administration for every medicine, to highlight the safest method of administration A user guide and tutorial to give new readers confidence in using and understanding the Guide Revised chapters on administration methods and devices, aseptic non-touch technique, and latex allergy Fully revised and expanded Y-site compatibility section Spiral binding to allow the book to be left open at the relevant page The Guide is also available electronically at www.uclhguide.com.
Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.
Effective risk communication is essential to the well-being of any organization and those people who depend on it. Ineffective communication can cost lives, money and reputations. Communicating Risks and Benefits: An Evidence-Based User’s Guide provides the scientific foundations for effective communications. The book authoritatively summarizes the relevant research, draws out its implications for communication design, and provides practical ways to evaluate and improve communications for any decision involving risks and benefits. Topics include the communication of quantitative information and warnings, the roles of emotion and the news media, the effects of age and literacy, and tests of how well communications meet the organization’s goals. The guide will help users in any organization, with any budget, to make the science of their communications as sound as the science that they are communicating.